The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which
inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit …

Direct oral anticoagulants (DOACs) have significantly improved the care of patients requiring
anticoagulation. With similar or better efficacy and safety outcomes and easier use in the …

Direct oral anticoagulants (DOACs) have been licensed worldwide for several years for
various indications. Each year, 10–15% of patients on oral anticoagulants will undergo an …

A universal anti‐Xa assay for the determination of rivaroxaban, apixaban and edoxaban
drug concentrations would simplify laboratory procedures and facilitate widespread …

Background Outcomes following andexanet alfa reversal of factor Xa inhibitors in patients
requiring urgent or emergent invasive procedures are lacking. This study aimed to describe …

Patients taking direct oral anticoagulants (DOACs) who then need an emergency invasive
procedure require specialized management strategies. Appropriate patient evaluation …

Low-dose rivaroxaban has been used in Asian patients with direct oral anticoagulants
(DOACs) eligible for atrial fibrillation (AF). However, there are few pharmacokinetic (PK) data …

Introduction To measure direct factor Xa inhibitor (apixaban, edoxaban, rivaroxaban)
concentrations, dedicated chromogenic anti‐Xa assays are recommended as suitable …

Essentials• The value of thrombin generation assay (TGA) in monitoring direct oral
anticoagulants (DOAC) is not well defined.• TGA parameters were measured and correlated …

Purpose The one-dose daily regime of rivaroxaban could cause a pronounced variability in
concentration and effect of which a deeper knowledge is warranted. This study aimed to …